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a b s t r a c t
Vascular endothelial growth factor (VEGF) has been characterized as a heparin binding angiogenic growth
factor displaying high speciﬁcity for endothelial cells. It is profoundly accumulated and co-localized with
amyloid beta (A) plaques in the brain of Alzheimer’s disease patients. In order to examine the effect
of A plaques on the expression level of VEGF mRNA and its receptors, brain tissue of both transgenic
Tg2576 and wild type mice at ages ranging from 13 to 22 months was subjected to in situ hybridization
followed by densitometric assessment using computer-assisted image analysis. Strong expression of
VEGF mRNA, fetal liver kinase (Flk)-1 mRNA, and neuropilin (Nrp)-1 mRNA in the piriform, entorhinal,
somatosensory, frontal cortex and hippocampal formation of both transgenic and non-transgenic mice
brain was detected. Developmentally, only expression of VEGF mRNA was increased with age in the
entorhinal, and somatosensory cortex of wild type mice. In 20-month-old transgenic Tg2576 mice, up-
regulation of VEGF mRNA, Flk-1 mRNA, and Nrp-1 mRNA transcripts was observed in the entorhinal
cortex compared to age-matched wild type mice. Our data suggest up-regulation of VEGF mRNA, Flk-1
mRNAandNrp-1mRNA, at least in the entorhinal cortex at ageswhenAdeposition in Tg2576 is typically
increasing.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease and is the leading cause of age related, irreversible demen-
tia. The AD is characterized by the extracellular deposition of senile
plaquesmainly formedof beta amyloid (A), intracellular neuroﬁb-
rilary tangles and neuronal loss (for reviews, see Schliebs, 2013;
Schliebs and Arendt, 2011).
Abundant evidence has already been reported on frequent
occurrence of vascular changes in AD patients (for review, see
Schliebs, 2013). The cerebrovascular abnormalities including thick-
ening of the microvascular basement membranes, decreased
luminal diameter, and microvascular degeneration, in particular
in the temporal-parietal cortex, have frequently been observed in
AD patients (for review, see Nicolakakis and Hamel, 2011) and
ultimately cause impaired cerebral perfusion (Kara et al., 2012).
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Already more than twenty years ago, a casual relationship between
vascular mechanism and development of sporadic AD has been
hypothesized (De la Torre and Mussivand, 1993; for reviews, see
Isingrini et al., 2009; Schliebs, 2013). The deposition of A in the
wall of cerebral blood vessels termed as cerebral amyloid angiopa-
thy (CAA) provokes the cerebrovascular abnormality in AD (for
review, see Schliebs, 2013). Besides, in vivo and in vitro studies
described A as inhibitor of angiogenesis (Paris et al., 2004a,b).
One of the key angiogenic factors, vascular endothelial growth
factor (VEGF), a highly conserved heparin-binding protein, was
originally found in vascular endothelial cells. It is able to induce
vascular endothelial cell proliferation, migration and vasoperme-
ability in many types of tissue (for review, see Schliebs, 2013). As it
has already been revealed, VEGF also exerts tropic and protective
actions on neurons (for review, see Rosenstein and Krum, 2004).
The broad bioactivities of VEGF are mediated mainly via interac-
tion with two different types of tyrosine kinase receptors, VEGF
receptor-1 (VEGFR-1, Flt-1) and VEGFR-2 (Flk-1/KDR) (Cao, 2009;
Darrington et al., 2012; Roskoski, 2008) and/or a non-tyrosine
kinase transmembrane glycoprotein, neuropilin (Nrp)-1/-2 (Bates
and Harper, 2002; Jain, 2003).
http://dx.doi.org/10.1016/j.ijdevneu.2015.03.003
0736-5748/© 2015 Elsevier Ltd. All rights reserved.
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The experimental brain contusion study in adult female
Sprague–Dawely rats revealed induction of VEGF, Flt-1, and Flk-1
mRNA expression and protein in and around the lesion follow-
ing traumatic brain injury (Sköld et al., 2005). We also reported
that cerebral endothelial cells derived from AD-transgenic Tg2576
mice brain exposed to hypoxic stress induced up-regulation of
VEGF secretion (Muche et al., 2013). These reports may suggest
the compensatory role of VEGF against the hypoperfusion and
ischemia by its crucial neovascularization activity. Besides, recent
studies have been reported up-regulation of VEGF in the cere-
brospinal ﬂuid and the peripheral blood (Corsi et al., 2011) and
signiﬁcant down-regulation in the serum (Huang et al., 2013) of
AD patients compared to the elderly control subjects. This is prob-
ably because of the strong binding afﬁnity of VEGF to A plaques
which may result in continuous deposition of VEGF in the amy-
loid plaques (Mateo et al., 2007). Notably, one week after injecting
A1-42 into rat hippocampus, the up-regulation of VEGF-A gene
with increased VEGF-A protein content of reactive astrocytes and
microglia was detected and was similar to those produced in late
onset AD brains (Chiarini et al., 2010) and may allow to trigger
angiogenesis andvascular amyloidbeta clearance. Studyconducted
on postmortem brains also conﬁrmed higher expression of VEGF
in the neurons and reactive astrocytes of the neocortex, and large
intraparenchymal vessels and capillaries of AD brain as compared
to the non-demented control subjects (Mateo et al., 2007b; Tang
et al., 2013). Even thought the reports described earlier support
the notion of VEGF valuable role in the neurodegenerative disease,
French case-control population study failed to obtain the associa-
tion between VEGF gene and risk of developing AD (Chapuis et al.,
2006).
Over thepast threedecades ago, the amyloid cascadehypothesis
of AD has placed the A, formed from the amyloid precursor pro-
tein (APP), central pillar in the process of AD pathogenesis (Hardy
and Higgins, 1992). As it has been reported, the APP expression is
increased following ischemic or hypoxic conditions, in turn stimu-
late the production anddeposition of Apeptide in the brain (Koike
et al., 2012; Liu et al., 2012); however, the molecular mechanic
associationbetween thesepathologies andprocessing of amyloido-
genic pathways is still a matter of debate. The up-regulation of
VEGF in response to hypoxic, ischemic or hypoglycemic stress (Iida
et al., 2002; Li et al., 2014; Muche et al., 2013), suggests its involve-
ment in the APP processing. Recently, it has been reported in brain
slices and primary neuronal cell cultures that VEGF may affect
APP processing (Bürger et al., 2009, 2010) The APP is also highly
expressed in the endothelium of neoforming vessels (Paris et al.,
2005), and inhibitors of ß- and -secretases have been reported
to inhibit angiogenesis and tumor growth (Paris et al., 2005),
suggesting a role of APP metabolism in the process of angiogen-
esis.
The aim of the present study was to test our hypothesis that the
deposition of A plaques may have a link with the expression of
VEGF mRNA in brain tissue of aged AD- transgenic Tg2576 mice.
To address this hypothesis, brain tissues obtained from mice at
ages ranging from 13 to 22 months of both AD-transgenic Tg2576
and wild type mice were subjected to semiquantitative in situ
hybridization (ISH) followed by quantitative assessment using
computer-assisted imageanalysis. Thedatapresentedhere indicate
differential pattern of expression of VEGF mRNA, Flk-1 mRNA and
Nrp-1 mRNA in cerebral cortical regions of AD-transgenic Tg2576
mice during aging, suggesting a role of A plaques deposition in
these processes, at least in the entorhinal cortex of transgenic
Tg2576 mice, and supporting our hypothesis.
2. Material and methods
2.1. Transgenic Tg2576 mouse
The Tg2576 mice contains as transgene human isoform APP695
with doublemutation Lys670 →AsnMet671 → Leu (K670N,M671L),
whichwas found ina largeSwedish familywithEOAD, asdeveloped
anddescribedpreviouslybyHsiaoet al. (1996). Themutatedhuman
APP695 was introduced into a hamster prion protein (PrP) cos-
mid vector in which the PrP open reading frame was replaced with
the variant APP-ORF. Then, the mutated human APP695 heterozy-
gote Tg2576 male mouse mate with female C57BL6/SJL mouse and
mostly resulting equal proportionof transgenic andnon-transgenic
wild type littermates. The transgenic Tg2576 mice progressively
develop A plaques in the cerebral cortex at ages of 10 months
onwards (Apelt et al., 2004). The transgenity of the mice was deter-
mined in tail tissue by PCR (Hsiao et al., 1996). The animals were
kept in a standard plastic cage maintained on 12/12h light/dark
cycle. Theywere fed commercially available normal diet and drink-
ing water ad libitum.
All mice used in this study were bred and kept in the animal
house of the Experimentelles Zentrum der Medizinischen Fakultät
der Universität Leipzig (MEZ) in accordance with the animal care
guidelines stipulated by the Animal Care and Use Committee at the
University of Leipzig, Germany, which is in agreement to the regu-
lationsof theEuropeanCommunityCouncilDirective (86/609/EEC).
In this study, male transgenic Tg2576 and wild type mice for each
age group (13, 16, 20 and 22 months) were used, where each group
contained ﬁve mice. Then, their transgenity was determined using
polymerase chain reaction (Fig. 1).
2.2. Tissue preparation
Mice were perfused under deep anesthesia with 50ml saline,
followed by 50ml of ﬁxative (4% paraformaldehyde in 0.1M
Fig. 1. Representative example of PCR genotyping for wild type (1, 2, 5, 8 and 10) and transgenic Tg2576 (3, 4, 6, 7, and 9) mice. Po =positive transgenic control; Ng=negative
control without APP gene. The APP gene (human APP gene: 430bp and murine APP gene: 703bp) were separated using 1% agarose gel.
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phosphate buffer, pH 7.4) using a peristaltic pump. After perfusion,
the brain was dissected from the skull, postﬁxed in the same ﬁxa-
tive overnight at 4 ◦C and cryoprotected in phosphate buffer saline
(PBS) with 30% sucrose. The cerebral cortex of the wild type and
Tg2576 transgenic mice brains were then coronally sectioned on a
microtome at 30m thickness. For each group, twenty sections of
tissue were kept to use for each expression analysis. The sectioned
brain slices were collected in sterile 24-well plates ﬁlled with
0.1M phosphate buffer (PB) pH 7.4/diethylpyrocarbonate (DEPC)
containing 0.05% Na-Azid and kept at 4 ◦C.
2.3. In situ hybridization
2.3.1. Preparation of riboprobes
Thepreparationof plasmids containing fragments ofVEGF, Flk-1
or Nrp-1 DNA was performed according to the following proto-
col: ampliﬁed DNA fragments of interest were cloned into plasmid
vector pGEM-T using the T/A Cloning Kit (Promega, Mannheim,
Germany), heat-shock transformed into magnesium-competent
Epicurian Coli XL1- Blue MRF’Kan cells and plated on blue/white
indicator plates. Bacteria from white colonies were propagated in
3ml LB culture and about 20mg plasmid DNA were prepared using
the Miniprep kit (Qiagen, Hilden, Germany). Plasmid DNAs were
screened for positive inserts and sequenced with M13 primers
using the AmpliTaq FS Big Dye terminator kit on an ABI 377 DNA
Sequensor (PE Applied Biosystems, Weiterstadt, Germany). Using
the T7 and Sp6 promoter of the pGEM-T vector the plasmids with
the VEGF, Nrp-1 and Flk-1 fragments were used as template to
generate digoxigenin (DIG)-labeled antisense and sense riboprobes
by in vitro transcription according to the manufacture’s protocol
(AMBION, Megascript). The speciﬁcity of the riboprobes to label
VEGF, Nrp-1 and Flk-1 mRNA in mouse brain tissue was proved by
Northern blot analysis.
2.3.2. In situ hybridization and immunohistochemistry
Following preservation of brain slices at 4 ◦C in a solution con-
taining Na-Azid, the slices were rinsed for 3×5min in PBS to
remove theNa-Azid, andacetylated in freshlyprepared0.25%acetic
acid/0.1M triethanolamine 2×5min. The acetylated sections were
washed 3×5min in PBS pH 7.4, and prehybridized for 6h at
pretested and determined temperature of 37 ◦C, 50 ◦C and 42 ◦C for
the VEGF, Flk-1 and Nrp-1 probes, respectively, in the hybridiza-
tion mix (50% formamide, 5× SSC, herring sperm DNA 40g/ml).
Thereafter, the solution of hybridization mix and 100–200ng of
probes were denatured for 5min at 80 ◦C. The brain slices were
then transferred and incubated with denatured solution overnight
at different temperature depending on the nature of the probe as
stated above. The brain tissues were rinsed and transferred shortly
in 5× saline-sodium citrate (SSC) at room temperature, 1h in 0.2×
SSC at 70 ◦C, 5min in 0.2× SSC at room temperature and equili-
brated for 5min in buffer-1 (0.1M maleic acid, 0.15M NaCl pH
7.5). Following one hour blocking of nonspeciﬁc binding in a solu-
tion containing buffer-1/2% fetal calf serum/0.3% triton X-100, the
brain sections were incubated in anti-DIG antibody conjugated to
alkaline phosphatase (1:2000) for 4h at room temperature on a
shaker. The slices were washed for 2×10min in buffer-1 and equi-
librated for 10minutes in buffer- 2 (0.1M Tris–HCL, 0.1M NaCl,
0.05M MgCl pH 9.5) on a shaker. The substrate reaction was con-
ducted in a solution containing nitro blue tetrazolium (100mg/ml
70%dimethylformamide,DMF), 5-Bromo-4-chloro-3-indolyl phos-
phate (50mg/ml 100% DMF), levamisol (100mg/ml H2O), buffer-2
and a drop of tween 20) at room temperature in darkness on a
shaker until sufﬁcient signal intensity was reached, and the reac-
tion was stopped by washing the slices in PBS. On the other hand,
the in situ hybridized brain sections were rinsed for 3×5min in
PBS. To visualize the blood vessels and primary astrocytes, the
Table 1
List of primers used.
Gene Sequence of primers Product size
VEGF Sense: GAG AGC AAC ATC
ACC ATG CAG
Antisense: TCA CCG CCT
TGG CTT GTC ACA T
281bp
VEGF-R2 (Flk-1) Sense: AGA ATG CGG GCT
CCT GAC TAC A
Antisense: CCG GGT GGT
GGA AAG AAC AAC
781bp
Nrp-1 Sense: GGC TGC CGT TGC
TGT GCG CCA
Antisense: ATA GCG GAT
GGA AAA CCC TGC
403bp
brain tissue was incubated with primary antibodies of polyclonal
anti-von Willebrandt Factor (AWF, 1:250; Sigma, Germany) and
monoclonal anti-glial ﬁbrillary acidic protein (anti-GFAP, 1:500;
Sigma, Germany), respectively, for 1h at room temperature and
then washed for 3×5min in PBS. To avoid the unspeciﬁc bind-
ing of secondary antibodies, the tissues were blocked with 2%
BSA/0.1% triton/TBS at room temperature for one hour and rinsed
for 3×5min in PBS. The primary brain cells were then incubated
with secondary antibodies goat anti-rabbit CY3 (1:100; Sigma,
Germany) and goat anti-mouse CY2 (1:100; Sigma, Germany) ﬁt-
ting to the respective above mentioned primary antibodies for 1h
at room temperature. Then, the brain tissue was incubated in 1%
thioﬂavin-S (beta amyloid speciﬁc stain) for 30min at room tem-
perature in dark. The tissues were then rinsed in distilled water for
1min and differentiated in 85% ethanol for 35min at room tem-
perature. The sections were then mounted onto the glass slide and
dried overnight, and cover slipped in entellan. The brain tissues
were ﬁnally examined under ﬂuorescence microscope ﬁtted with
an AxioCam camera. Hybridizations with sense RNA probes were
considered as control Table 1.
2.3.3. Image analysis of ISH
Exactly the same regions of brain slices derived from both
transgenic Tg2576 mice and corresponding wild type control were
identiﬁed and the same intensity of lightwas applied duringmicro-
scopic examination. The identiﬁed images of ISH were captured
using a Zeiss Axioplan 2 microscope ﬁtted with AxioCam camera.
Besides, the same parameters were applied while taking digital
photography. Measurements of signal intensity were conducted
from 20 sections per animal. For both transgenic Tg2576 mice
and the corresponding non-transgenic wild type mice brain slices,
an area of 100m×100m (entorhinal, piriform cortex, substan-
tia nigra and striatum) and 60m×60m (hippocampus and
somatosensory cortex) were used to measure hybridization signal
intensity by densitometry using Image J software. The intensity of
different regions of brain section of both transgenic tg2576 and
corresponding wild type mice were quantiﬁed using equal area of
measurement as it is already mentioned. For each measurement,
the background of the tissue slices was considered as reference
whichwas later subtracted frommeasuredvalueof eachexpression
signal of Tg2576 or wild type mice. Then, the mean values of each
measurement of a speciﬁc region of the tissue derived fromTg2576
mouse was divided by the mean value of the corresponding wild
type mice and multiplied by 100% and taken as percentage change
of expression related to A deposition. The same principle was
applied for the age related expression of VEGF mRNA, Flk-1 mRNA
and Nrp-1 mRNA. Finally, the data were analyzed using one-way
analysis of variance (ANOVA), followed by Student’s t-test analysis.
28 A. Muche et al. / Int. J. Devl Neuroscience 43 (2015) 25–34
Fig. 2. Representative examples of VEGF mRNA (D, G & K), Flk-1 mRNA (E, H & L) and Nrp-1 mRNA (F, I & M) expression throughout the brain of an adult wild type mouse as
revealed by ISH using a digoxigenin-labeled riboprobes. Scale bar: 100m.
Hybridization of brain sections with corresponding sense riboprobes were considered as control, and did not show any speciﬁc hybridization signal (A–C). TH – thalamus,
HP – hypothalamus, LSA – lateral septal area, CPu – caudate putamen (striatum), Pir – piriform cortex, PO – preoptical area, Amy – amygdaloid , SC – superior colliculus , Aq
– aqueduct , SN – substantia nigra, MM – mammilary bodies, Ent – entorhinal cortex.
2.4. Statistical analysis
All data were presented as mean± SEM. Statistical comparison
between experimental groups were tested using one-way analysis
of variance (ANOVA), followed by a Student’s t-test analysis
using SPSS software. P-values <0.05 were considered statistically
signiﬁcant.
3. Results
As VEGF has been found to be up-regulated in the brain
of Alzheimer patients (Desai et al., 2009; Tang et al., 2013),
the present study was undertaken to disclose whether the
changes in VEGF expression are related to the accumulation of
-amyloid deposits. Using the Tg2576 mice as an appropriate ani-
mal model of AD, the aging-related expression of VEGF mRNA,
Flk-1 mRNA and Nrp-1 mRNA was investigated in cerebral cor-
tical brain regions by non-radioactive ISH applying DIG-labeled
riboprobes.
3.1. Expression pattern of VEGF mRNA, Flk-1 mRNA and Nrp-1
mRNA in mice brain tissue
In Fig. 2 representative examples of adult mice brain tissue
hybridized with digoxigenin-labeled riboprobes to detect expres-
sion of VEGF mRNA, Flk-1 mRNA, and Nrp-1 mRNA are shown at
lowermagniﬁcation. The ISH demonstrated similar expression pat-
tern of VEGF mRNA, Flk-1 mRNA, and Nrp-1 mRNA throughout the
brain (Fig. 2D–I and K–M), while no staining was observed when
sections were hybridized with corresponding sense probes (con-
sidered as controls, Fig. 2A–C)
3.1.1. VEGF mRNA expression
High staining intensities of VEGF mRNA were observed in the
cerebral cortical regions, such as piriform, entorhinal, somatosen-
sory and frontal cortices, as well as in the hippocampal formation
(Fig. 2D, G and K), while, moderate intensities of hybridization
signals were detected in the thalamus, hypothalamus, lateral sep-
tal area, mammilary bodies and preoptical area (Fig. 2D, G and
K). No or faint staining was observed in caudate putamen (stria-
tum), amygdala, superior colliculus and substantia nigra (Fig. 2D, G
and K).
3.1.2. Flk-1 mRNA expression
Similar to VEGF transcripts expression, the highest intensi-
ties of the hybridization signals of Flk-1 mRNA were observed in
the piriform, entorhinal, somatosensory and frontal cortices, as
well as in the hippocampal formation of brain section (Fig. 2E,
H and L). On the other hand, a lower staining was detected
in the caudate putamen (striatum), amygdaloid, superior colli-
culi and substantia nigra (Fig. 2E, H and L). Moderate staining
was observed in subcortical regions such as thalamus, hypotha-
lamus, lateral septal area, mammilary bodies and preoptical area
(Fig. 2E, H and L).
3.1.3. Nrp-1 mRNA expression
The distribution pattern of Nrp-1 mRNA appears to be similar
to that of Flk-1 mRNA. The highest intensities of the hybridization
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Fig. 3. Representative examples of the regional distribution of VEGF mRNA (A, B, D), Flk-1 mRNA (D–F) and Nrp-1 mRNA (G–I) expression in different brain regions, including
entorhinal cortex (A, D, G), hippocampus and forebrain (B, E, H) and frontal cortex (C, F, I representing a higher magniﬁcation of the box of image B, E, H, respectively). Sections
obtained from a 22-month-old mouse brain were subjected to in situ hybridization labeling of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA used for determination messenger
RNAs signals. Scale bar: 50m.
signal of Nrp-1 mRNA were observed in the piriform, entorhinal,
somatosensory and frontal cortices, as well as in the hippocampal
formation (Fig. 2F, I and M) while lower hybridization signal was
detected in the caudate putamen (striatum), amygdaloid, superior
colliculi and substantia nigra (Fig. 2F, I and M). On the other hand,
moderate intensities of hybridization signals of Nrp-1 mRNA were
observed in subcortical regions such as thalamus, hypothalamus,
lateral septal area, mammilary bodies and preoptical area (Fig. 2F,
I and M).
3.2. Age-related changes of VEGF mRNA, Flk-1 mRNA and Nrp-1
mRNA expression in brains of non-transgenic wild type and
transgenic Tg2576 mice
To determine age-related changes in expression pattern of VEGF
mRNA, Flk-1 mRNA and Nrp-1 mRNA brain sections obtained from
transgenic Tg2576 and non-transgenic wild type mice at differ-
ent ages were subjected to ISH followed by densitometric analysis
of the intensities of hybridization signals in the brain regions
of interest. The representative example for the determination of
transcripts signaling is designated in Fig. 3A–I. The data were
expressed as percentage change of the hybridization intensity in
a particular brain region (mean optical density) compared to that
detected in the corresponding brain region from 13-month-old
mice.
In the somatosensory cortex of wild type mice, the age-related
expression level of Flk-1 mRNA and Nrp-1 mRNA did not signiﬁ-
cantly change between ages of 13 months and 22 months, while
the expression of VEGF mRNA was found to be up-regulated at
ages of 20 and 22 months by about 30% and 40%, respectively,
as compared to the corresponding level of expression detectable
in mice at the age of 13 months (data not shown). On the other
hand, the expression of VEGF mRNA and Flk-1 mRNA signiﬁcantly
up-regulated in the somatosensory cortex of transgenic Tg2576
mice at 22-months by 25% and 34%, respectively, as compared to
the corresponding level of expression detectable in mice at the age
of 13 months (data not shown).
In the entorhinal cortex of non-transgenic mice, the expression
of VEGF mRNA and Nrp-1 mRNA was signiﬁcantly up-regulated
by 33% and 20% (P<0.05), respectively, but not earlier than at
the age of 22 months as compared to the corresponding level of
expression detected inmice at the age of 13months (Fig. 4A). How-
ever, signiﬁcant age-related change in expression of Flk-1 mRNA
between ages of 13 months and 22 months was not observed.
In transgenic Tg2576 mice the expression of VEGF mRNA was
signiﬁcantly up-regulated at the age of 20- and 22- months by 33%
and 35%, respectively, as compared to the corresponding level of
expression detected in mice at the age of 13 months (Fig. 4B). The
expression of Flk-1 mRNA and Nrp-1 mRNA, on the other hand,
was signiﬁcantly up-regulated by 23% and 25%, respectively, from
22-months of age onwards, as compared to the corresponding
level of expression detectable in transgenic Tg2576 mice at the
age of 13 months (Fig. 4B).
In the hippocampal formation, regardless of the subﬁelds
examined, no signiﬁcant age related changes in the expression
level of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA were observed
during aging from 13 months onwards. On the other hands,
in transgenic Tg2576 mice, signiﬁcant up- regulation of VEGF
mRNA expression was detected at the age of 22-months (data not
shown).
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3.3. Effect of -amyloid deposition on expression of VEGF
mRNA, Flk-1 mRNA and Nrp-1 mRNA in brain tissue of
transgenic Tg2576 mice
To prove the age-related accumulation of -amyloid deposits,
brain sections of Tg2576 mice were stained with thioﬂavin-S, a
ﬂuorescent dye which is known to label senile plaques. As rep-
resentatively shown in Fig. 5B-E, double immuneﬂuorescent (with
anti-GFAP andAWF) followedby thioﬂavin-S stainedbrain sections
from Tg2576 mice comprising the entorhinal cortex demonstrate
an age-dependent increase in the number of -amyloid plaques
starting at the age of 13 months, but progressively rising with fur-
ther aging up to 22months of age (Fig. 5B–E)which is accompanied
with high expression of glial cells, such as astrocytes. In contrast,
no deposition of -amyloid plaques was detected in brain sec-
tions obtained from non-transgenic littermates (Fig. 5A). Hence,
to determine the effect of age-related accumulation of A on the
expression level of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA
densitometric analysis of ISH signals in regions with high plaque
load (Tg2576 mice) were compared with that in the corresponding
regions ofwild typemice (no plaque deposits). For this purpose, the
hippocampal formation and the entorhinal cortex were selected
for semiquantitative evaluation as representative brain regions
displaying high plaque burden in Tg2576 mice (Kuznetsova and
Schliebs, 2013).
In the entorhinal cortex of 13- and 16-months-old Tg2576mice,
there was no statistically signiﬁcant difference in expression level
of VEGFmRNA, Flk-1mRNA andNrp-1mRNA in comparison to that
detected in the corresponding non-transgenic littermates. How-
ever, in 20- and 22-month-old transgenic Tg2576, the expression
of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA in the entorhinal
cortical expression was signiﬁcantly up-regulated as compared to
the corresponding level of expression detected in non-transgenic
littermates (Fig. 6).
In the hippocampal formation of Tg2576 mice comprising the
CA1 to CA3 subﬁelds and DG, the expression level of Flk-1 mRNA
and Nrp-1 mRNA did not show signiﬁcant changes as compared
to that detected in the corresponding regions of non-transgenic
littermates, regardless of the age examined. In contrast, in 20- and
22- month-old Tg2576 mice, the expression level of VEGF mRNA
detected in the CA2 and CA3 subﬁelds was increased by about 20%
and 25% (P<0.05), respectively, as compared to the corresponding
regions of non-transgenic mouse littermates (data not shown).
Fig. 6. Changes of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA expression levels
in the entorhinal cortex derived from 13-, 16-, 20- and 22- month-old transgenic
Tg2576 mice as compared to non-transgenic littermates. Data are expressed as
percentage change of gene expression level in transgenic Tg2576 mice over the cor-
responding non-transgenic wild type mice (=100%), and represent the mean± SEM
of ﬁve animals.
*P<0.05 vs non-transgenic wild type mice, one-way ANOVA followed by Student’s
t-test.
4. Discussion
Themain ﬁndings of the present study indicated the presence of
strong expression of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA in
the piriform, entorhinal, somatosensory and frontal cortices aswell
as hippocampal formation of both AD-transgenic Tg2576 mice and
non-transgenic littermates brain. In non-transgenic wild type mice
the expression of VEGF mRNA in the entorhinal cortex increased
from age of 20 months onwards, while in 20- and 22- month-old
AD-transgenic Tg2576 with high A-plaque load an up-regulation
of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA transcripts was
observed in the entorhinal cortex as compared to age-matched
non-transgenic wild type mice.
4.1. Regional distribution of VEGF mRNA, Flk-1 mRNA and Nrp-1
mRNA transcripts in mice brain tissues
The mRNA transcripts of VEGF, Flk-1, and Nrp-1 were strongly
expressed in the piriform, entorhinal, somatosensory and frontal
cortices, and hippocampus. On the other hand, lower hybridization
signals of VEGFmRNA, Flk-1mRNAandNrp-1mRNAweredetected
in the caudate putamen (striatum), amygdaloid, superior colliculi
and substantia nigra.
Our ﬁnding is supported by the ISH and reverse transcription-
polymerase chain reaction (RT-PCR) data demonstrated time
dependant up-regulation of VEGF mRNA and Flk-1 mRNA in the
entorhinal denervated hippocampus possibly suggesting the con-
tribution of VEGF in the structural reformation of deafferenated
hippocampus througheitherdirect or indirect promotionofneurite
growth (Wang et al., 2005).
Besides, very recent ISH and RT-PCR and immunoﬂuorescence
studies have reported highest intensity of VEGF-receptor 3 expres-
sion in the olifacyory bulbs, piriform cortex, anterodorsal thalamic
nucleus, several nuclei of hypothalamus, the brainstem cranial
nerve nuclei (Hou et al., 2011), and subventricular zone and retinal
marginal zone of the adult forebrain (Choi et al., 2010). Moreover,
signiﬁcant up-regulation of VEGF-receptor has been reported in
the subgranular zone (Gage et al., 1998) and ischemic hippocam-
pus presumably indicated the ﬁrm relationship between induction
of VEGF expression and hippocampal neurogenesis after ischemic
injury (Shin et al., 2008). The expressions of VEGF and its receptors
of thepresent studymay reﬂect regional variation invasculardistri-
bution and vascular density. This probably indicates the existence
of considerable regional endothelial heterogeneity in the brain (Ge
et al., 2005) and may underscore asymmetrical gene expression in
different parts of normal brain (Berchtold et al., 2008).
Double immunoﬂuorescent staining has been demonstrated
colocalization of neuropilin-1 and VEGF to cerebral blood ves-
sels and activated astrocytes and may suggest the contribution
of neuropilin-1 to neovascular formation in the adult ischemic
brain neurons (Zhang et al., 2001). Similarly, in the present study,
strongest expression of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA
detected in different parts of cerebral cortex including entorhinal
cortex and hippocampus conceivably demonstrated the existence
of increased vascular distribution and networking.
4.2. Age-related changes in expression of VEGF mRNA, Flk-1
mRNA and Nrp-1 mRNA in mice brain tissues
In order to elucidate age-related change in the expression of
VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA, ISH was carried out in
brain sections derived from transgenic Tg2576 and non-transgenic
littermate mice of age ranging from 13 months to 22 months.
The VEGF mRNA expression in the entorhinal and somatosen-
sory cortex of aged 22-month-old non-transgenic mice was found
to be signiﬁcantly up-regulated. Immunohistochemical study on
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Fig. 4. Age-related changes in expression of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA in the entorhinal cortex of non-transgenic wild type (A) and transgenic Tg2576
mice (B). Brain sections obtained from mice at different ages were subjected to ISH followed by densitometric analysis of the intensities of hybridization signals. Data were
expressed as percentage change of hybridization signal compared to that detected in the corresponding brain region from 13-month-old mice (=100%), and represent the
mean± SEM of ﬁve mice.
*P<0.05 compared to 13-month-old mice, one-way ANOVA followed by Student’s t-test.
Fig. 5. Representative examples of brain sections derived from transgenic Tg2576 mice of 13- (B), 16- (C), 20- (D) and 22- month-old (E), stained with double immuneﬂuo-
rescent stain (anti-GFAP and AWF for astrocytes and endothelial cells lining the blood vessels, respectively) followed by thioﬂavin-S to label -amyloid plaques. The images
demonstrate the age-related accumulation of -amyloid deposits (black star) and expression of astrocytes (white arrow) and endothelial cells lining the blood vessels (black
arrow) in and around the entorhinal cortex, whereas no plaques were found in brain sections from non-transgenic littermates (A). Scale bar: 50m, 20×.
32 A. Muche et al. / Int. J. Devl Neuroscience 43 (2015) 25–34
fresh autopsy reported that angiogenesis in the cerebral cortex
increaseswith gestational age until about 30–35weeks of gestation
(Mito et al., 1991). Besides, comparative study on the expression
pattern of VEGF in the developing and adult mouse using ISH has
been demonstrated the highest level of VEGF-b expression in the
adult mouse brain compared to the developing mouse especially
in the hippocampus and all layers of cerebral cortex (Lagercrantz
et al., 1998). In response to stroke, the aged rat brain is also capa-
ble to induce the up-regulated expression of angiogenic genes like
VEGF (Buga et al., 2008) and enhance a vigorous process of angio-
genesis, which probably suggest the induction of brain plasticity in
the aged brain as feedback against stroke (Buga et al., 2014) and
maintain the regulation of angiogenesis and vascular remodeling
(Buga et al., 2008).
Unlike the entorhinal and somatosensory cortex, the expres-
sion of VEGF mRNA in the hippocampus of the present study
remained unaltered with age. This may indicate the complexity of
gene expression in different regions of the brain across lifespan of
the rats. Similarly, Berchotold and collaborators (2008) reported
relatively stable gene expression proﬁle in the hippocampus of
cognitive intact normal aged individuals (Berchtold et al., 2008).
In another study, the VEGF expression at the neurovascular units
was not affected in hippocampus of normal aged C57B1/6J mice
(Murugesan et al., 2012).
VEGF acts by binding to two tyrosine-kinase receptors, VEGF
receptor-1 (VEGFR-1 or Flt-1) and VEGF receptor-2 (VEGFR-2 or
KDR or Flk-1), as both are almost exclusively expressed in ECs
(Ferrara et al., 1992). It has been reported a signiﬁcant increased
expression of Flk-1 and Flt-1 at the neurovascular unit of aged hip-
pocampus (Murugesan et al., 2012). Likewise, Smith and Steinle
(2007) indicated signiﬁcant increase in protein levels of VEGFR2 in
22- and32-month-old rats as compared to 8-month-old rats (Smith
and Steinle, 2007). Similarly in the present study, the expression
of Flk-1 mRNA was signiﬁcantly upregulated in transgenic Tg2576
mice.
In summary, in non- transgenic and transgenic Tg2576 mice,
different cortical parts of cerebrumdemonstrated substantially dif-
ferent gene expression with age.
4.3. Effect of -amyloid deposition on expression of VEGF
mRNA, Flk-1 mRNA and Nrp-1 mRNA in mice brain tissues
The AD-transgenic Tg2576 mice used in this study, produce
human A peptides and deposited in the brain parenchyma in age-
dependant manner (Fig. 5B–E). The AD-transgenic Tg2576 mice
exhibited a six-fold higher expression of Swedish double mutation
ofhumanAPPanddemonstratedhigher cerebral cortical deposition
of A plaques from 10-month-old age onwards (Apelt et al., 2004).
Thus, the AD-transgenic Tg2576 mice appears to be an appropriate
animalmodel to address our particular research questionswhether
there is a potential link between expression of VEGF mRNA and
its receptor mRNA, and co-receptor and A deposition in cere-
bral cortical regions. Therefore, brain sections derived from both
AD-transgenic Tg2576 mice and non-transgenic mice at ages rang-
ing from 13 months to 22 months were subjected to ISH to label
VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA, and subsequently,
incubated with double immuneﬂuorescent stain (anti-GFAP and
AWF for astrocytes and endothelial cells lining the blood vessels,
respectively) followed by thioﬂavin-S for visualization of amyloid
plaques.
In the present study, the in situ hybridized brain sections
showeda signiﬁcant up-regulationofVEGFmRNAat age20months
onwards in the entorhinal cortex and hippocampal formation of
AD-transgenic Tg2576 mice, as compared to age-matched non-
transgenic wild type mice. Our ISH ﬁndings compared well with
immunohistochemistry data reported byKouznetsova et al. (2006).
Similarly, increased level of VEGF protein has been observed in
the cerebral cortex from 22-month-old Tg2576 mice assayed by
ELISA (Bürger et al., 2009). Enhanced VEGF immunoreactivity in
the entorhinal cortex and hippocampus (Tang et al., 2013), as well
as increased VEGF level in the cerebrospinal ﬂuid and periph-
eral blood of AD patients have also been detected (Corsi et al.,
2011). Furthermore, in the brain of AD patients increased intrathe-
cal level of VEGF and high expression of VEGF in neuronal and
glial cells were observed (Tang et al., 2013; Tarkowski et al.,
2002). This up-regulation of both VEGF protein and mRNA may
be considered as the consequence of the A-mediated cerebrovas-
cular impairments and damages of microvasculature as recently
observed in brains of aged Tg2576 mice (Kuznetsova and Schliebs,
2013).
As it has already been reported, besides the initiation of angio-
genesis, VEGF is also used to promote the neurite maturation
in the primary neural culture and organotypic cortical explants
(Khaibullina et al., 2004; Pitzer et al., 2003; Rosenstein et al., 2003).
The expression of VEGF exerts its action through activation of its
receptors and co-receptor, Nrp-1 which is co-localized with Flk-1
(for review, see Koch et al., 2011). Supplementary administration
of VEGF in the fetal neocortical explants and VEGF infusion in the
brain resulted in the increased expression of Flk-1 on neuronal
process (Rosenstein et al., 2003). The expression of Flk-1 is also
increased in the brain tissue after ischemic condition (Narasimhan
et al., 2009) and brain injuries (Ye et al., 2012). On the other
hand, the occlusion of middle cerebral artery resulted in the up-
regulation of Nrp-1 (Hou et al., 2008; Whitehead et al., 2010). It
has been reported in recent study that the increased expression
of Nrp-1 has also been detected following acute optic nerve injury
(Nitzan et al., 2006). Similarly, in this study, the expression level of
Flk-1 mRNA and Nrp-1 mRNA in the entorhinal cortex was signif-
icantly increased in Tg2576 mice not earlier than at the age of 20
months, as compared to age-matched not-transgenic mice. Recent
study has indicated that transplantation of Flk-1 and human bone
marrow-derived mesenchymal stem cells promotes angiogenesis
and neurogenesis after cerebral ischemia in rats (Bao et al., 2011).
This may suggest the fundamental mediatory role of receptor as
well as co-receptor in the angiogenic and neurogenic action of
VEGF.
In summary, the data presented here indicate differential pat-
tern of expression of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA
in cerebral cortical regions of AD-like Tg2576 mice during aging,
suggesting a role of A deposits in these processes, at least in the
entorhinal cortex of transgenic Tg2576 mice.
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